Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Toulouse – page 30

1 504 clinical trials in Toulouse, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Toulouse at a glance
1 504
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 504 trials in Toulouse

Open in trial search

Squamous cell carcinoma of head and neck

Recruiting

Study on Reducing Chemotherapy Cycles with Pembrolizumab for Patients with PD-L1-Positive Recurrent or Metastatic Head and Neck Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Oncopole Claudius Regaud

Aplasia pure red cell

Recruiting

Study on Isatuximab for Treating Pure Red Cell Aplasia in Patients with Major ABO Mismatch After Stem Cell Transplantation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Isatuximab
  • Sponsor:Assistance Publique Hopitaux De Paris

Atrial fibrillation+3

Recruiting

Study on the Effects of Ticagrelor and Rivaroxaban in Patients with Atrial Fibrillation After Coronary Stent Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Insel Gruppe AG

Colon cancer

Recruiting

Study on Using Oxaliplatin, Fluorouracil, and Folinic Acid for Treating Stage II Colon Cancer in Patients with Positive Circulating Tumor DNA

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Colorectal cancer metastatic

Recruiting

Study on Bevacizumab-Based Chemotherapy for Patients with Unresectable Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Neurogenic bladder

Recruiting

Study on E. coli Polysaccharide for Reducing Antibiotic Use in Patients with Neurogenic Bladder and Recurrent Urinary Tract Infections

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:E.coli Polysaccharide
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Crohn's disease

Recruiting

Study Comparing Azathioprine and Methotrexate with Adalimumab for Patients with Crohn's Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

C3 glomerulopathy

Recruiting

Study on Long-Term Effects of Iptacopan in Patients with C3 Glomerulopathy or Idiopathic Immune-Complex Membranoproliferative Glomerulonephritis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Pemphigus

Recruiting

Study on Personalized Maintenance Therapy with Rituximab and Corticosteroids for Patients with Pemphigus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Centre Hospitalier Universitaire Rouen

BRAF V600E mutation positive+1

Recruiting

Study on the Effectiveness and Safety of Plixorafenib (FORE8394) for Patients with Cancer Having BRAF Alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cobicistat
  • Sponsor:Fore Biotherapeutics Inc.

Von Willebrand's disease

Recruiting

Study on Preventing Bleeding in Children with Severe von Willebrand Disease Using Vonicog Alfa and Octocog Alfa

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Octocog Alfa
  • Sponsor:Takeda Development Center Americas Inc.

Thermal burn

Recruiting

Study on Antibiotic Prophylaxis with Piperacillin, Tazobactam, and Cefazolin for Burn Patients Undergoing Excision-Graft Surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cefazolin
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Toulouse

What the registry says about research in the country

01 Cardiovascular and Metabolic Research

Innovative studies focusing on heart disease treatment, including trials for TTR amyloidosis and prevention of heart failure. Advanced therapeutic approaches using novel compounds like baxdrostat in combination with established medications.

  • TTR Amyloidosis Cardiomyopathy
  • Heart Failure Prevention
  • Cardiovascular Risk Management
02 Oncology Studies

Comprehensive cancer research targeting multiple types of malignancies, including head and neck cancer, gastric cancer, and advanced pancreatic cancer. Novel approaches using targeted therapies and immunotherapy combinations.

  • Head & Neck Squamous Cell Carcinoma
  • Gastric and GEJ Cancer
  • Pancreatic Cancer
  • Non-Small Cell Lung Cancer
03 Neurological Disorders

Advanced research in neurodegenerative conditions and movement disorders, including studies on frontotemporal dementia, essential tremor, and traumatic brain injury outcomes.

  • Frontotemporal Dementia
  • Essential Tremor
  • Traumatic Brain Injury
  • Multiple Sclerosis
04 Autoimmune and Inflammatory Conditions

Studies investigating new treatments for inflammatory diseases, including innovative approaches for Crohn's disease, psoriatic arthritis, and myasthenia gravis.

  • Crohn's Disease
  • Psoriatic Arthritis
  • Myasthenia Gravis
  • Idiopathic Pulmonary Fibrosis
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.